Vicus Capital Makes New $281,000 Investment in CVS Health Corporation (NYSE:CVS)

Vicus Capital acquired a new stake in CVS Health Corporation (NYSE:CVS - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 4,147 shares of the pharmacy operator's stock, valued at approximately $281,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in CVS. Dodge & Cox boosted its stake in shares of CVS Health by 11.2% in the fourth quarter. Dodge & Cox now owns 70,105,899 shares of the pharmacy operator's stock valued at $3,147,054,000 after buying an additional 7,075,209 shares in the last quarter. Capital World Investors lifted its holdings in CVS Health by 26.6% in the fourth quarter. Capital World Investors now owns 61,039,777 shares of the pharmacy operator's stock valued at $2,739,927,000 after acquiring an additional 12,819,148 shares during the period. Geode Capital Management LLC grew its stake in shares of CVS Health by 2.6% during the 4th quarter. Geode Capital Management LLC now owns 27,051,540 shares of the pharmacy operator's stock worth $1,211,582,000 after purchasing an additional 689,867 shares during the period. Capital International Investors increased its holdings in shares of CVS Health by 4.8% in the 4th quarter. Capital International Investors now owns 26,666,401 shares of the pharmacy operator's stock valued at $1,196,989,000 after purchasing an additional 1,212,126 shares in the last quarter. Finally, Pzena Investment Management LLC lifted its stake in shares of CVS Health by 49.3% in the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator's stock valued at $880,319,000 after purchasing an additional 6,475,271 shares during the period. Institutional investors and hedge funds own 80.66% of the company's stock.

Insider Buying and Selling

In other news, Director Guy P. Sansone acquired 1,570 shares of the business's stock in a transaction dated Thursday, June 5th. The shares were bought at an average cost of $63.70 per share, for a total transaction of $100,009.00. Following the acquisition, the director now directly owns 12,007 shares in the company, valued at $764,845.90. This trade represents a 15.04% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.22% of the stock is currently owned by company insiders.

CVS Health Trading Down 0.3%

CVS traded down $0.19 during trading on Thursday, hitting $66.91. The company's stock had a trading volume of 5,208,935 shares, compared to its average volume of 10,943,569. CVS Health Corporation has a twelve month low of $43.56 and a twelve month high of $72.51. The stock has a market cap of $84.64 billion, a PE ratio of 15.97, a PEG ratio of 0.96 and a beta of 0.56. The firm's 50 day moving average price is $65.02 and its 200-day moving average price is $60.30. The company has a debt-to-equity ratio of 0.77, a current ratio of 0.82 and a quick ratio of 0.63.

CVS Health (NYSE:CVS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The pharmacy operator reported $2.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.63. CVS Health had a return on equity of 10.59% and a net margin of 1.39%. The firm had revenue of $94.59 billion for the quarter, compared to analyst estimates of $93.07 billion. During the same period last year, the company earned $1.31 EPS. The firm's quarterly revenue was up 7.0% on a year-over-year basis. On average, analysts expect that CVS Health Corporation will post 5.89 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Mizuho upped their price target on CVS Health from $70.00 to $76.00 and gave the stock an "outperform" rating in a report on Wednesday, April 9th. Royal Bank Of Canada upped their target price on CVS Health from $74.00 to $81.00 and gave the company an "outperform" rating in a report on Monday, May 5th. Robert W. Baird lifted their price target on CVS Health from $51.00 to $71.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. Barclays set a $79.00 price objective on shares of CVS Health and gave the company an "overweight" rating in a research note on Monday, June 2nd. Finally, Wall Street Zen upgraded shares of CVS Health from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Two research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $74.75.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.